Literature DB >> 26392112

Protein arginine methyltransferase 1 promoted the growth and migration of cancer cells in esophageal squamous cell carcinoma.

Weizheng Zhou1, Hui Yue2, Chunguang Li1, Hezhong Chen1, Yang Yuan3.   

Abstract

Dysregulation of protein arginine methyltransferase 1 (PRMT1) has been reported in several cancer types. However, its expression pattern and biological functions in esophageal squamous cell carcinoma (ESCC) remained unknown. Here, we have found that the expression of PRMT1 was up-regulated in ESCC samples. In the biological function studies, forced expression of PRMT1 promoted the growth and migration of ESCC cells. However, knocking down the expression of PRMT1 inhibited the growth, migration, and metastasis of ESCC cells. Moreover, PRMT1 activated Hedgehog signaling and up-regulated the expression of target genes downstream of Hedgehog signaling. Taken together, our study revealed the oncogenic roles of PRMT1 in the progression of ESCC, and PRMT1 might be a promising therapeutic target for the treatment of ESCC.

Entities:  

Keywords:  Cell growth and migration; ESCC; Hedgehog signaling; PRMT1

Mesh:

Substances:

Year:  2015        PMID: 26392112     DOI: 10.1007/s13277-015-4098-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  28 in total

1.  Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers.

Authors:  Masanori Yoshimatsu; Gouji Toyokawa; Shinya Hayami; Motoko Unoki; Tatsuhiko Tsunoda; Helen I Field; John D Kelly; David E Neal; Yoshihiko Maehara; Bruce A J Ponder; Yusuke Nakamura; Ryuji Hamamoto
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

Review 2.  The physiological and pathophysiological role of PRMT1-mediated protein arginine methylation.

Authors:  Thomas B Nicholson; Taiping Chen; Stéphane Richard
Journal:  Pharmacol Res       Date:  2009-07-28       Impact factor: 7.658

3.  Alternative splicing yields protein arginine methyltransferase 1 isoforms with distinct activity, substrate specificity, and subcellular localization.

Authors:  Isabelle Goulet; Gabrielle Gauvin; Sophie Boisvenue; Jocelyn Côté
Journal:  J Biol Chem       Date:  2007-09-11       Impact factor: 5.157

Review 4.  Molecular pathology and potential therapeutic targets in esophageal basaloid squamous cell carcinoma.

Authors:  Tsuyoshi Saito; Hiroyuki Mitomi; Takashi Yao
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 5.  Hedgehog pathway aberrations and gastric cancer; evaluation of prognostic impact and exploration of therapeutic potentials.

Authors:  Omar Abdel-Rahman
Journal:  Tumour Biol       Date:  2015-02-14

6.  Novel inhibitors for PRMT1 discovered by high-throughput screening using activity-based fluorescence polarization.

Authors:  Myles B C Dillon; Daniel A Bachovchin; Steven J Brown; M G Finn; Hugh Rosen; Benjamin F Cravatt; Kerri A Mowen
Journal:  ACS Chem Biol       Date:  2012-04-20       Impact factor: 5.100

Review 7.  Hedgehog signaling pathway and cancer therapeutics: progress to date.

Authors:  Joshua M Ruch; Edward J Kim
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

8.  Dimethylarginine metabolism during acute and chronic rejection of rat renal allografts.

Authors:  Dariusz Zakrzewicz; Anna Zakrzewicz; Sigrid Wilker; Rolf-Hasso Boedeker; Winfried Padberg; Oliver Eickelberg; Veronika Grau
Journal:  Nephrol Dial Transplant       Date:  2010-07-19       Impact factor: 5.992

9.  Arginine methylation of the c-Jun coactivator RACO-1 is required for c-Jun/AP-1 activation.

Authors:  Clare C Davies; Atanu Chakraborty; Markus E Diefenbacher; Mark Skehel; Axel Behrens
Journal:  EMBO J       Date:  2013-04-26       Impact factor: 11.598

Review 10.  Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas.

Authors:  Afroz Abidi
Journal:  Indian J Pharmacol       Date:  2014 Jan-Feb       Impact factor: 1.200

View more
  6 in total

1.  PRMT1 expression predicts sensitivity to platinum-based chemotherapy in patients with ovarian serous carcinoma.

Authors:  Hiroaki Matsubara; Takeshi Fukuda; Yuichiro Awazu; Shigenori Nanno; Masahiro Shimomura; Yuta Inoue; Makoto Yamauchi; Tomoyo Yasui; Toshiyuki Sumi
Journal:  Oncol Lett       Date:  2020-12-31       Impact factor: 2.967

2.  Arginine methylation of SMAD7 by PRMT1 in TGF-β-induced epithelial-mesenchymal transition and epithelial stem-cell generation.

Authors:  Yoko Katsuno; Jian Qin; Juan Oses-Prieto; Hongjun Wang; Olan Jackson-Weaver; Tingwei Zhang; Samy Lamouille; Jian Wu; Alma Burlingame; Jian Xu; Rik Derynck
Journal:  J Biol Chem       Date:  2018-06-15       Impact factor: 5.157

Review 3.  Protein arginine methyltransferases: promising targets for cancer therapy.

Authors:  Jee Won Hwang; Yena Cho; Gyu-Un Bae; Su-Nam Kim; Yong Kee Kim
Journal:  Exp Mol Med       Date:  2021-05-18       Impact factor: 8.718

4.  Gene silencing of galectin-3 changes the biological behavior of Eca109 human esophageal cancer cells.

Authors:  Lili Qiao; Ning Liang; Jian Xie; Hui Luo; Jingxin Zhang; Guodong Deng; Yupeng Li; Jiandong Zhang
Journal:  Mol Med Rep       Date:  2015-11-10       Impact factor: 2.952

5.  Downregulation of PRMT1 promotes the senescence and migration of a non-MYCN amplified neuroblastoma SK-N-SH cells.

Authors:  Yu-Jen Lee; Wen-Wei Chang; Chien-Ping Chang; Tsung-Yun Liu; Chun-Yi Chuang; Kun Qian; Y George Zheng; Chuan Li
Journal:  Sci Rep       Date:  2019-02-11       Impact factor: 4.379

6.  Esophageal Squamous Cell Carcinoma Is Accompanied by Local and Systemic Changes in L-arginine/NO Pathway.

Authors:  Iwona Bednarz-Misa; Paulina Fortuna; Mariusz G Fleszar; Łukasz Lewandowski; Dorota Diakowska; Joanna Rosińczuk; Małgorzata Krzystek-Korpacka
Journal:  Int J Mol Sci       Date:  2020-08-30       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.